The Experts below are selected from a list of 213360 Experts worldwide ranked by ideXlab platform
Kazuki Nishida - One of the best experts on this subject based on the ideXlab platform.
-
Clinical features and Treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki NishidaAbstract:Background Treatment Modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative Treatment. In this study, tumor characteristics of DF, transition of the Treatment Modality, and clinical outcome of surgical Treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. Methods Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical Treatment. Results The number of registered patients increased gradually. The frequency of surgical Treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin ( P = 0.34). Conclusions The Treatment Modality has shifted from surgical to conservative Treatment, with risk factors for surgical Treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
-
clinical features and Treatment outcome of desmoid type fibromatosis based on a bone and soft tissue tumor registry in japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki NishidaAbstract:Treatment Modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative Treatment. In this study, tumor characteristics of DF, transition of the Treatment Modality, and clinical outcome of surgical Treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical Treatment. The number of registered patients increased gradually. The frequency of surgical Treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34). The Treatment Modality has shifted from surgical to conservative Treatment, with risk factors for surgical Treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
Yoshihiro Nishida - One of the best experts on this subject based on the ideXlab platform.
-
Clinical features and Treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki NishidaAbstract:Background Treatment Modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative Treatment. In this study, tumor characteristics of DF, transition of the Treatment Modality, and clinical outcome of surgical Treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. Methods Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical Treatment. Results The number of registered patients increased gradually. The frequency of surgical Treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin ( P = 0.34). Conclusions The Treatment Modality has shifted from surgical to conservative Treatment, with risk factors for surgical Treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
-
clinical features and Treatment outcome of desmoid type fibromatosis based on a bone and soft tissue tumor registry in japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki NishidaAbstract:Treatment Modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative Treatment. In this study, tumor characteristics of DF, transition of the Treatment Modality, and clinical outcome of surgical Treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical Treatment. The number of registered patients increased gradually. The frequency of surgical Treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34). The Treatment Modality has shifted from surgical to conservative Treatment, with risk factors for surgical Treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
Tsuneharu Miki - One of the best experts on this subject based on the ideXlab platform.
-
analysis of nocturia with 24 h urine volume nocturnal urine volume nocturnal bladder capacity and length of sleep duration concept for effective Treatment Modality
BJUI, 2011Co-Authors: Masahiro Nakao, Hisashi Honjo, Osamu Ukimura, Hiroshi Kitakoji, Akihiro Kawauchi, Tsuneharu MikiAbstract:OBJECTIVE • To determine the relationship between the number of nocturia and 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration as well as to assess the significance of these factors with respect to eliminating nocturnal voidings in individual patients with nocturia. PATIENTS AND METHODS • Among 532 participants who completed a 3-day bladder diary between April 2005 and December 2006, the diaries of 450 participants without 24-h polyuria were analyzed. • Clinical variables such as the number of daytime and night-time voids, 24-h urine volume, nocturnal polyuria index, daytime and night-time maximum voided volumes (MW), night/day MW ratio, sleep duration and proportion of night/day urine production rates were obtained from each diary. • Participants were classified into eight groups according to values of three factors: nocturnal MW, proportion of night/day urine production rates and length of sleep duration. • Each group was divided into three subgroups: non-nocturics (number of nocturnal voidings is zero), mild nocturics (number of nocturnal voidings is one) and severe nocturics (number of nocturnal voidings is two or more). • The data from non-nocturics with three normal factors were regarded as the normal control and compared with the variables of the other subgroups using Dunnett's method. RESULTS • Variables that form the basis of classifying participants into eight groups and corresponding to abnormal factors of each group were statistically significant in all the subgroups of each group. • Furthermore, a significantly increased 24-h urine volume was found in severe nocturics of the group with three normal factors. • A significantly decreased 24-h urine volume was found in non-nocturics of groups with nocturnal polyuria, decreased bladder capacity and both long sleep duration and nocturnal polyuria. • A significantly increased nocturnal MW and night/day MW ratio were shown in non-nocturics and mild nocturics of the groups with nocturnal polyuria and both long sleep duration and nocturnal polyuria. CONCLUSIONS • Because nocturia is a multifactorial disorder and closely related to four factors (i.e. 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration), the evaluation of all these factors appears to be clinically useful for determining the main contributing factor in patients with nocturia as well as the suitable Treatment Modality on an individual basis. • Physicians should take all these factors into consideration in the evaluation and Treatment of nocturia.
-
Analysis of nocturia with 24‐h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration: concept for effective Treatment Modality
BJUI, 2010Co-Authors: Masahiro Nakao, Hisashi Honjo, Osamu Ukimura, Hiroshi Kitakoji, Akihiro Kawauchi, Tsuneharu MikiAbstract:OBJECTIVE • To determine the relationship between the number of nocturia and 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration as well as to assess the significance of these factors with respect to eliminating nocturnal voidings in individual patients with nocturia. PATIENTS AND METHODS • Among 532 participants who completed a 3-day bladder diary between April 2005 and December 2006, the diaries of 450 participants without 24-h polyuria were analyzed. • Clinical variables such as the number of daytime and night-time voids, 24-h urine volume, nocturnal polyuria index, daytime and night-time maximum voided volumes (MW), night/day MW ratio, sleep duration and proportion of night/day urine production rates were obtained from each diary. • Participants were classified into eight groups according to values of three factors: nocturnal MW, proportion of night/day urine production rates and length of sleep duration. • Each group was divided into three subgroups: non-nocturics (number of nocturnal voidings is zero), mild nocturics (number of nocturnal voidings is one) and severe nocturics (number of nocturnal voidings is two or more). • The data from non-nocturics with three normal factors were regarded as the normal control and compared with the variables of the other subgroups using Dunnett's method. RESULTS • Variables that form the basis of classifying participants into eight groups and corresponding to abnormal factors of each group were statistically significant in all the subgroups of each group. • Furthermore, a significantly increased 24-h urine volume was found in severe nocturics of the group with three normal factors. • A significantly decreased 24-h urine volume was found in non-nocturics of groups with nocturnal polyuria, decreased bladder capacity and both long sleep duration and nocturnal polyuria. • A significantly increased nocturnal MW and night/day MW ratio were shown in non-nocturics and mild nocturics of the groups with nocturnal polyuria and both long sleep duration and nocturnal polyuria. CONCLUSIONS • Because nocturia is a multifactorial disorder and closely related to four factors (i.e. 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration), the evaluation of all these factors appears to be clinically useful for determining the main contributing factor in patients with nocturia as well as the suitable Treatment Modality on an individual basis. • Physicians should take all these factors into consideration in the evaluation and Treatment of nocturia.
Chung Yin Kong - One of the best experts on this subject based on the ideXlab platform.
-
pancreatic cancer Treatment costs including patient liability by phase of care and Treatment Modality 2000 2013
Medicine, 2019Co-Authors: Angela C Tramontano, Yufan Chen, Tina R Watson, Andrew Eckel, Deirdre F Sheehan, Mary Linton B Peters, Pari V Pandharipande, Chung Yin KongAbstract:OBJECTIVES: Our study provides phase-specific cost estimates for pancreatic cancer based on stage and Treatment. We compare Treatment costs between the different phases and within the stage and Treatment Modality subgroups. METHODS: Our cohort included 20,917 pancreatic cancer patients from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database diagnosed between 2000 and 2011. We allocated costs into four phases of care-staging (or surgery), initial, continuing, and terminal- and calculated the total, cancer-attributable, and patient-liability costs in 2018 US dollars. We fit linear regression models using log transformation to determine whether costs were predicted by age and calendar year. RESULTS: Monthly cost estimates were high during the staging and surgery phases, decreased over the initial and continuing phases, and increased during the three-month terminal phase. Overall, the linear regression models showed that cancer-attributable costs either remained stable or increased by year, and either were unaffected by age or decreased with older age; continuing phase costs for stage II patients increased with age. CONCLUSIONS: Our estimates demonstrate that pancreatic cancer costs can vary widely by stage and Treatment received. These cost estimates can serve as an important baseline foundation to guide resource allocation for cancer care and research in the future.
-
esophageal cancer Treatment costs by phase of care and Treatment Modality 2000 2013
Cancer Medicine, 2019Co-Authors: Angela C Tramontano, Yufan Chen, Tina R Watson, Andrew Eckel, Chung Yin KongAbstract:BACKGROUND: Detailed cost estimates are not widely available for esophageal cancer. Our study estimates phase-specific costs for esophageal cancer by age, year, histology, stage, and Treatment for older patients in the United States and compares these costs within stage and Treatment modalities. METHODS: We identified 8061 esophageal cancer patients in the Surveillance, Epidemiology, and End Results-Medicare database for years 1998-2013. Total, cancer-attributable, and patient-liability costs were calculated based on separate phases of care-staging (or surgery), initial, continuing, and terminal. We estimated costs by Treatment Modality within stage and phase for esophageal adenocarcinoma and squamous cell carcinoma separately. We fit linear regression models using log transformation to determine cost by age and calendar year. All costs are reported in 2018 US dollars. RESULTS: Overall, mean (95% CI) monthly total cost estimates were high during the staging ($8953 [$8385-$9485]) and initial phases ($7731 [$7492-$7970]), decreased over the continuing phase ($2984 [$2814-$3154]), and increased substantially during the 6-month terminal phase ($18 150 [$17 211-$19 089]). This pattern of high staging and initial phase costs, decreasing continuing phase costs, and increasing terminal phase costs was seen in all stages. The highest staging costs were in stages III ($9249, $8025-$10 474) and II ($9171, $7642-$10 699). The highest initial phase cost was in stage IV, $9263 ($8758-49 768), the lowest continuing phase cost was in stage I, $2338 ($2160-$2517), and the highest terminal phase costs were in stages II ($20 533, $17 772-$23 293) and III ($20 599, $18 268-$22 929). The linear regression models showed that cancer-attributable costs remained stable over the study period and were unaffected by age for most histology, stage, and Treatment Modality subgroups. CONCLUSIONS: Our estimates demonstrate that esophageal cancer costs can vary widely by histology, stage, and Treatment. These cost estimates can be used to guide future resource allocation for esophageal cancer care and research.
Toshiyuki Kunisada - One of the best experts on this subject based on the ideXlab platform.
-
Clinical features and Treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki NishidaAbstract:Background Treatment Modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative Treatment. In this study, tumor characteristics of DF, transition of the Treatment Modality, and clinical outcome of surgical Treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. Methods Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical Treatment. Results The number of registered patients increased gradually. The frequency of surgical Treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin ( P = 0.34). Conclusions The Treatment Modality has shifted from surgical to conservative Treatment, with risk factors for surgical Treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
-
clinical features and Treatment outcome of desmoid type fibromatosis based on a bone and soft tissue tumor registry in japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki NishidaAbstract:Treatment Modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative Treatment. In this study, tumor characteristics of DF, transition of the Treatment Modality, and clinical outcome of surgical Treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan. Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical Treatment. The number of registered patients increased gradually. The frequency of surgical Treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34). The Treatment Modality has shifted from surgical to conservative Treatment, with risk factors for surgical Treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.